Surgeons warn that colorectal cancer is now the leading cause of cancer death in people under 50, and subtle symptoms are too often dismissed.
A 2026 systematic review finds semaglutide and tirzepatide carry a higher hair-loss signal than older GLP-1 drugs — though the shedding appears reversible.
Prediction-market firm Kalshi has opened contracts on whether drugs will hit their endpoints or win FDA approval, raising fresh insider-trading and ethics concerns.
The company said its next-generation pyruvate kinase activator failed to show enough differentiation, ceding ground to a rival Novo Nordisk therapy.
Ervebo is licensed against one Ebola species, but new human data suggest it may help against the Bundibugyo strain now driving a fast-growing outbreak.
A new American Heart Association statement draws a sharp line between moderate coffee and concentrated caffeine products.
The complaint claims Lilly compared its highest doses against lower doses of Novo’s drugs — escalating a bitter rivalry in the weight-loss market.
The Series B will fund Phase 2 and Phase 3 studies of dotinurad, a uric-acid-lowering therapy already approved in several Asian markets.
Newly disclosed documents show Vertex was the only bidder left standing after a months-long courtship of the acromegaly drugmaker.
The FDA's accelerated approval of zidesamtinib gives GSK its first lung cancer medicine and a foothold in a small but hard-to-treat group of ROS1-positive patients.